

**Synthesis, characterization, DNA/BSA/HSA interactions, molecular modeling,  
antibacterial and *in vitro* cytotoxic activities of a novel parent and niosome nano-  
encapsulated Ho(III) complex**

**Deng Yinhua <sup>a,b</sup>, Mohammad Mehdi Foroughi <sup>c</sup>, Zahra Aramesh-Boroujeni <sup>d</sup>, Shohreh Jahani <sup>e,\*</sup>,  
Mohadess Peydayesh <sup>f,\*</sup>, Fariba Borhani <sup>g,\*</sup>, Mehrdad Khatami <sup>e,h</sup>, Meysam Rohani <sup>i</sup>, Michal Dusek <sup>j</sup>,  
Vaclav Eigner <sup>j</sup>**

<sup>a</sup> Department of Pharmacy, Hunan Provincial Peoples Hospital, Changsha 410005, PR. China

<sup>b</sup> Department of Pharmacy, The First Hospital Affiliated to Hunan Normal University, Changsha 410005, PR. China

<sup>c</sup> Department of Chemistry, Kerman Branch, Islamic Azad University, Kerman, Iran

<sup>d</sup> Department of Clinical Laboratory, AlZahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

<sup>e</sup> Nanobioelectrochemistry Research Center, Bam University of Medical Sciences, Bam, Iran

<sup>f</sup> Clinical Research Center, Pastor Educational Hospital, Bam University of Medical Sciences, Bam, Iran

<sup>g</sup> Medical Ethics and Law Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>h</sup> Cell Therapy and Regenerative Medicine Comprehensive Center, Kerman University of Medical Sciences, Kerman, Iran

<sup>i</sup> Department of Medicine, Medical School, Bam University of Medical Sciences, Bam, Iran

<sup>j</sup> Institute of Physics of the Czech Academy of Sciences, Na Slovance 2, 18221 Prague 8, Czech Republic

\*Corresponding Author: Tel.: +98 35331321750

E-mails: [shohre\\_jahani@yahoo.com](mailto:shohre_jahani@yahoo.com), [drpedayesh57@gmail.com](mailto:drpedayesh57@gmail.com), [faribaborhani@msn.com](mailto:faribaborhani@msn.com)

**Table S1.** Selected bond lengths (Å) and angles (°) for [Ho(bpy)(H<sub>2</sub>O)<sub>6</sub>]Cl<sub>3</sub>

Bond lengths			
X-Y	X-Y (Å)	X-Y	X-Y (Å)
Ho1-O1w	2.317(3)	Ho2-O7w	2.317(3)
Ho1-O2w	2.320(3)	Ho2-O8w	2.332(3)
Ho1-O3w	2.371(3)	Ho2-O9w	2.377(3)
Ho1-O4w	2.326(3)	Ho2-O10w	2.326(3)
Ho1-O5w	2.309(3)	Ho2-O11w	2.302(3)
Ho1-O6w	2.349(3)	Ho2-O12w	2.375(3)
Ho1-N1a	2.492(5)	Ho2-N1b	2.479(5)
Ho1-N2a	2.486(5)	Ho2-N2b	2.492(5)

Bond angles			
X-Y-Z	X-Y-Z (°)	X-Y-Z	X-Y-Z (°)
O1w-Ho1-O2w	74.44(12)	O7w-Ho2-O8w	73.60(12)
O1w-Ho1-O3w	74.65(13)	O7w-Ho2-O9w	73.39(14)
O1w-Ho1-O4w	141.69(13)	O7w-Ho2-O10w	141.25(13)
O1w-Ho1-O5w	98.39(12)	O7w-Ho2-O11w	100.68(13)
O1w-Ho1-O6w	147.00(13)	O7w-Ho2-O12w	147.03(13)
O1w-Ho1-N1a	71.94(13)	O7w-Ho2-N1b	94.01(15)
O1w-Ho1-N2a	96.49(14)	O7w-Ho2-N2b	71.26(13)
O2w-Ho1-O3w	74.55(12)	O8w-Ho2-O9w	75.29(13)
O2w-Ho1-O4w	74.37(11)	O8w-Ho2-O10w	74.52(12)
O2w-Ho1-O6w	128.38(12)	O8w-Ho2-O12w	148.19(12)
O2w-Ho1-N1a	124.77(13)	O8w-Ho2-N1b	75.44(15)
O3w-Ho1-O4w	76.04(12)	O9w-Ho2-O10w	77.69(13)
O4w-Ho1-O5w	96.50(11)	O10w-Ho2-O11w	94.92(12)
O5w-Ho1-O6w	73.58(12)	O11w-Ho2-O12w	73.36(11)
O6w-Ho1-N1a	75.12(12)	O12w-Ho2-N1b	72.15(13)
N1a-Ho1-N2a	65.20(17)	N1b-Ho2-N2b	65.91(17)

**Table S2.** Hydrogen-bond geometry ( $\text{\AA}$ ,  $^\circ$ ) for the title compound.

D–H…A	D–H ( $\text{\AA}$ )	H…A ( $\text{\AA}$ )	D…H ( $\text{\AA}$ )	D–H…A ( $^\circ$ )
O1w–H1o1w…Cl5 <sup>i</sup>	0.82(3)	2.53(4)	3.096(4)	128(4)
O1w–H2o1w…Cl6 <sup>ii</sup>	0.82(3)	2.27(3)	3.060(4)	161(4)
O2w–H1o2w…Cl2 <sup>i</sup>	0.82(3)	2.28(3)	3.084(4)	166(3)
O2w–H2o2w…Cl3	0.820(15)	2.40(2)	3.083(4)	141(3)
O3w–H1o3w…Cl6 <sup>iii</sup>	0.82(3)	2.37(3)	3.154(3)	161(4)
O3w–H2o3w…Cl5 <sup>i</sup>	0.820(14)	2.359(17)	3.110(4)	153(4)
O4w–H1o4w…Cl3	0.82(3)	2.31(3)	3.083(4)	157(4)
O4w–H2o4w…Cl5	0.82(2)	2.31(2)	3.093(3)	161(3)
O5w–H1o5w…Cl6 <sup>iv</sup>	0.82(3)	2.34(3)	3.122(3)	158(3)
O5w–H2o5w…Cl5 <sup>v</sup>	0.82(3)	2.25(3)	3.047(3)	165(3)
O6w–H1o6w…Cl2	0.82(3)	2.27(3)	3.074(4)	167(3)
O6w–H2o6w…Cl6 <sup>iv</sup>	0.82(3)	2.29(3)	3.075(4)	160(3)
O7w–H1o7w…Cl4	0.82(3)	2.58(4)	3.080(4)	121(4)
O7w–H2o7w…Cl1 <sup>vi</sup>	0.82(2)	2.30(3)	3.068(4)	157(3)
O8w–H1o8w…Cl3	0.82(3)	2.29(3)	3.083(4)	161(4)
O8w–H2o8w…Cl2	0.820(11)	2.34(3)	3.086(4)	152(4)
O9w–H1o9w…Cl4	0.82(3)	2.37(2)	3.136(4)	155(4)
O9w–H2o9w…Cl1	0.82(3)	2.34(2)	3.144(3)	167(4)
O10w–H1o10w…Cl2	0.82(2)	2.27(2)	3.077(3)	166(4)
O10w–H2o10w…Cl4 <sup>vii</sup>	0.82(3)	2.27(2)	3.072(4)	166(3)
O11w–H1o11w…Cl1 <sup>viii</sup>	0.82(3)	2.31(3)	3.105(3)	165(3)
O11w–H2o11w…Cl4 <sup>vi</sup>	0.82(3)	2.24(3)	3.057(3)	171(3)
O12w–H2o12w…Cl3 <sup>vii</sup>	0.82(3)	2.31(3)	3.107(4)	165(3)
C3a–H1c3a…Cl1 <sup>iv</sup>	0.96	2.95	3.593(5)	126
C4a–H1c4a…Cl2 <sup>iv</sup>	0.96	2.61	3.532(5)	161
C7a–H1c7a…Cl2 <sup>iv</sup>	0.96	2.88	3.835(8)	177
C9a–H1c9a…Cl4	0.96	2.91	3.612(6)	131
C2b–H1c2b…Cl5	0.96	2.90	3.628(7)	133
C3b–H1c3b…Cl1 <sup>iii</sup>	0.96	2.92	3.879(6)	173
C7b–H1c7b…Cl3 <sup>ix</sup>	0.96	2.61	3.513(5)	157
C8b–H1c8b…Cl6 <sup>vi</sup>	0.96	2.87	3.555(5)	129
C10b–H1c10b…Cl4 <sup>vi</sup>	0.96	2.93	3.888(5)	174

Symmetry codes: (i)  $1+x, y, z$ ; (ii)  $2-x, 1-y, -z$ ; (iii)  $x, 1+y, z$ ; (iv)  $1-x, 1-y, -z$ ; (v)  $1-x, 2-y, -z$ ; (vi)  $1-x, 1-y, 1-z$ ;(vii)  $-1+x, y, z$ ; (viii)  $-x, 1-y, 1-z$ ; (ix)  $1-x, 2-y, 1-z$ .

**Table S3.** Energy transfer efficiency E, overlap integral J, the binding distance to tryptophan residue of protein r and Förster critical distance  $R_0$  upon interaction of Ho(III) complex with BSA and HAS ([BSA]=[Ho(III) complex]=1.58  $\mu\text{M}$ , [HSA]=[Ho(III) complex]=2.0  $\mu\text{M}$ , T=298 K and  $\lambda_{\text{ex}}=280 \text{ nm}$ ).


Protein	E	J ( $\text{cm}^3 \text{ L mol}^{-1} \times 10^{-13}$ )	$R_0$ (nm)	r (nm)
<b>BSA</b>	0.20	4.3	2.3	2.7
<b>HSA</b>	0.22	4.5	2.2	2.7

**Table S4.** Binding energies and inhibition constants of investigated complex for DNA, BSA and HSA binding site.


<b>Macromolecule</b>	<b>Binding Energy (KCal.Mol<sup>-1</sup>)</b>	<b>K<sub>i</sub> (μM)</b>
<b>DNA</b>	-5.31	128.14
<b>BSA</b>	-3.67	596.61
<b>HSA</b>	-4.80	304.65

**Table S5:** The drug concentration causing a 50% reduction in cellular viability (IC50) of the Ho(III) complex and NN-En-Ho against of the MCF-7 and A-549 cell lines.


Cell lines	The drug concentration causing a 50% reduction in cellular viability (IC50) ( $\mu\text{g/ml}$ )	
	Ho(III) complex	NN-En-Ho
MCF-7	<b>7.23<math>\pm</math>0.01</b>	<b>4.69<math>\pm</math>0.02</b>
A-549	<b>11.45<math>\pm</math>0.03</b>	<b>7.71<math>\pm</math>0.01</b>




**Figure S1.** A polyhedral representation of  $[\text{Ho}(\text{bpy})(\text{H}_2\text{O})_6]\text{Cl}_3$ .




**Figure S2.** Hydrogen bonds in structure  $[\text{Ho}(\text{bpy})(\text{H}_2\text{O})_6]\text{Cl}_3$ .



**Figure S3.** FT-IR spectra of a) bpy, b)  $[\text{Ho}(\text{bpy})(\text{H}_2\text{O})_6]\text{Cl}_3$  complex.



**Figure S4.** (A) The UV-Vis spectra of the Ho(III) complex in methanol. Ho(III) complex Concentration:  $5 \times 10^{-3}$  M. (B) Emission spectrum of Ho(III) complex  $\lambda_{\text{ex}} = 280$  nm in methanol at room temperature. Ho(III) complex Concentration:  $5 \times 10^{-3}$  M.



**Figure S5.** Effect of increasing amounts of Ho(III) complex on the viscosity of FS-DNA in the Tris-HCl buffer solution.